Are mesenchymal stem cells able to manage cytokine storm in COVID-19 patients? A review of recent studies.

Autor:	Kaffash Farkhad N; Immunology Research Center, Department of Immunology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.; Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran., Reihani H; Department of Emergency Medicine, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran., Sedaghat A; Fellowship of Critical Care Medicine (FCCM), Lung Disease Research Center, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran., Moghadam AA; Specialty of Internal Medicine and Critical Care, Head of Army Hospital ICU and Intensivist, Iran., Moghadam AB; Internal Medicine and Critical Care, Department of Anesthesiology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran., Tavakol-Afshari J; Immunology Research Center, Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Jazyk:	angličtina
Zdroj:	Regenerative therapy [Regen Ther] 2021 Dec; Vol. 18, pp. 152-160. Date of Electronic Publication: 2021 Jun 08.
DOI:	10.1016/j.reth.2021.05.007
Abstrakt:	The Covid-19 disease has recently become one of the biggest challenges globally, and there is still no specific medication. Findings showed the immune system in severe Covid-19 patients loses regulatory control of pro-inflammatory cytokines, especially IL-6 production, called the "Cytokine storm" process. This process can cause injury to vital organs, including lungs, kidneys, liver, and ultimately death if not inhibited. While many treatments have been proposed to reduce cytokine storm, but the safety and effectiveness of each of them are still in doubt. Mesenchymal stem cells (MSCs) are multipotent cells with self-renewal potential capable of suppressing overactive immune responses and leading to tissue restoration and repair. These immuno-modulatory properties of MSCs and their derivatives (like exosomes) can improve the condition of Covid-19 patients with serious infectious symptoms caused by adaptive immune system dysfunction. Many clinical trials have been conducted in this field using various MSCs around the world. Some of these have been published and summarized in the present article, while many have not yet been completed. Based on these available data, MSCs can reduce inflammatory cytokines, increase oxygen saturation, regenerate lung tissue and improve clinical symptoms in Covid-19 patients. The review article aims to collect available clinical data in more detail and investigate the role of MSCs in reducing cytokine storms as well as improving clinical parameters of Covid-19 patients for use in future clinical studies. Competing Interests: All authors declare that they have no competing interests. (© 2021 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu